To determine if patients whose tumors had low T-cell infiltration at baseline may also benefit from canakinumab, as observed in CANOPY-1, the percentage of viable tumor cells in different arms was explored in patients with low CD8+ T-cell infiltration. This evidence concerns the gene CD8A and neoplasm.